Demetrios Kalaitzidis

Demetrios Kalaitzidis is an accomplished professional in the field of Immuno-Oncology, currently serving as Executive Director of Research Innovation at CRISPR Therapeutics since December 2015. Kalaitzidis has held various leadership positions at CRISPR Therapeutics, including Senior Director and Director, focusing on the development of CAR-T immunotherapies using CRISPR-Cas9 genome editing technology. Prior to this role, Kalaitzidis gained experience as an Assistant in Biology at Massachusetts General Hospital and as an Instructor at Harvard Medical School. Additionally, a postdoctoral fellow at Boston Children's Hospital and Harvard Medical School further enhanced Kalaitzidis's expertise. Educational credentials include a Ph.D. in Molecular and Cellular Biology, and Biochemistry, as well as a B.A. in Biology, both from Boston University.